Skip to main content

Advertisement

SpringerLink
Log in

Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia

  • Article
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

The aim of the present study was to investigate the epidemiologic evolution of fluoroquinolone resistance of E. coli clinical isolates from patients admitted to a hematology-oncology service where fluoroquinolone prophylaxis during neutropenia was recommended as the standard of care for many years but was then discontinued in a trial conducted in patients with acute leukemia. Fluoroquinolones had been shown to decrease the incidence of gram-negative bacteremia in cancer patients with neutropenia, yet it was thought that the emergence of resistance in Escherichia coli and other gram-negative bacteria may have caused a progressive lack of efficacy of fluoroquinolone prophylaxis. Epidemiologic surveillance of fluoroquinolone resistance of E. coli clinical isolates at our cancer center since 1992 showed a continuing influx of new clones not previously observed in the population of cancer patients, an increase in the number of cancer patients per year colonized and/or infected by fluoroquinolone-resistant E. coli (1992–1994, 10–16 patients; 1995–1997, 24–27 patients), and a resistance rate of >50% among E. coli bloodstream isolates of hematology-oncology patients. A 6-month fluoroquinolone prophylaxis discontinuation intervention trial in 1998 suggested that despite increasing resistance among E. coli isolates, fluoroquinolone prophylaxis in acute leukemia patients was still effective in the prevention of gram-negative bacteremia (incidence rates, 8% during the pre-intervention period vs. 20% after discontinuation; p<0.01). The resumption of fluoroquinolone prophylaxis in acute leukemia patients thereafter decreased the incidence of gram-negative bacteremia to the pre-intervention level (9%; p=0.03), while the proportion of in vitro fluoroquinolone resistance in E. coli bacteremia isolates again increased (from 15% during the intervention period to >50% in the post-intervention period). Relative rates of resistance thus were a poor indicator of the potential clinical benefits associated with fluoroquinolone prophylaxis in cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Bodey GP (1988) Antimicrobial prophylaxis for infection in neutropenic patients. Curr Clin Topics Infect Dis 9:1–43

    Google Scholar 

  2. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KVI, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751

    Article  PubMed  Google Scholar 

  3. Kern WV (2001) Current epidemiology of infections in neutropenic cancer patients. In: Rolston KVI, Rubenstein EB (eds) Febrile neutropenia. Martin Dunitz, London, pp 57–90

    Google Scholar 

  4. Zinner SH(1999) Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 29:490–494

    Google Scholar 

  5. Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A, Concia E (1996) Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 23:795–805

    CAS  PubMed  Google Scholar 

  6. Engels E, Lau J, Barza M (1998) Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 16:1179–1187

    CAS  PubMed  Google Scholar 

  7. Rotstein C, Mandell LA, Goldberg N (1997) Fluoroquinolone prophylaxis for profoundly neutropenic cancer patients: a meta-analysis. Curr Opin Oncol 4(Suppl 2):S2–S7

    Google Scholar 

  8. Kern WV, Kurrle E (1991) Ofloxacin versus trimethoprim-sulfamethoxazole for infection prevention in acute leukemia. Infection 19:73–80

    Google Scholar 

  9. Kern WV (1998) Epidemiology of fluoroquinolone-resistant Escherichia coli among neutropenic cancer patients. Clin Infect Dis 27:235–237

    Google Scholar 

  10. Liang RH, Yung RW, Chan TK, Chau PY, Lam WK, So SY, Todd D (1990) Ofloxacin versus cotrimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrob Agents Chemother 34:215–218

    Google Scholar 

  11. Talbot GH, Cassileth PA, Paradiso L, Correa-Coronas R, Bond L (1993) Oral enoxacin for infection prevention in adults with acute non-lymphocytic leukemia. Antimicrob Agents Chemother 37:474–482

    Google Scholar 

  12. Ball P (1995) Is resistant Escherichia coli bacteremia an inevitable outcome for neutropenic patients receiving a fluoroquinolone as prophylaxis? Clin Infect Dis 20:561–563

    Google Scholar 

  13. Murphy M, Brown AE, Sepkowitz KA, Bernard EM, Kiehn TE, Armstrong D (1997) Fluoroquinolone prophylaxis for the prevention of bacterial infection in patients with cancer—is it justified? Clin Infect Dis 25:346–347

    Google Scholar 

  14. Nucci M, Pulcheri W, Spector N, Bueno AP, Silveira S, Marangoni D, Ferreira R, Pacheco de Oliveira H (1994) Quinolone prophylaxis in neutropenic patients: efficacy versus resistance. Oncol Reports 1:1101–1105

    Google Scholar 

  15. Young LS (1988) Antimicrobial prophylaxis in the neutropenic host: lessons from the past and perspectives for the future. Eur J Clin Microbiol Infect Dis 7:93–97

    Google Scholar 

  16. Carratala J, Fernandez-Sevilla A, Tubau F, Dominguez MA, Gudiol F (1996) Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother 40:503–505

    Google Scholar 

  17. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F (1995) Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 20:557–560

    Google Scholar 

  18. Cometta A, Calandra T, Bille J, Glauser MP (1994) E. coli resistant to fluoroquinolones in patients with cancer and neutropenia. New Engl J Med 330:1240–1241

    Google Scholar 

  19. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R (1994) Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 38:681–687

    Google Scholar 

  20. Lang A, de Fina G, Meyer R, Aschbacher R, Rizza F, Mayr O, Casini M (2001) Comparison of antimicrobial use and resistance of bacterial isolates in a haematology ward and an intensive care unit. Eur J Clin Microbiol Infect Dis 20:657–660

    Google Scholar 

  21. Perea S, Hidalgo M, Arcediano A, Ramos MJ, Gomez C, Hornedo J, Lumbreras C, Folgueira D, Cortes-Funes H, Rodriguez-Noriega A (1999) Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis. J Antimicrob Chemother 44:117–120

    Google Scholar 

  22. Somolinos N, Arranz R, del Rey MC, Jimenez ML (1992) Superinfections by Escherichia coli resistant to fluoroquinolones in immunocompromised patients. J Antimicrob Chemother 30:730–731

    Google Scholar 

  23. van Belkum A, Goessens W, van der Schee C, Lemmens-den Toom N, Vos MC, Cornelissen J, Lugtenburg E, de Marie S, Verbrugh H, Lowenberg B, Endtz H (2001) Rapid emergence of ciprofloxacin-esistant enterobacteriaceae containing multiple gentamicin resistance associated integrons in a Dutch hospital. Emerg Infect Dis 7:862–871

    Google Scholar 

  24. van Kraaij MGJ, Dekker AW, Peters E, Fluit A, Verdonck LF, Rozenberg-Arska M (1998) Emergence and infectious complications of ciprofloxacin-resistant Escherichia coli in haematological cancer patients. Eur J Clin Microbiol Infect Dis 17:591–592

    Google Scholar 

  25. von Baum H, Franz U, Geiss HK (2000) Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients. Infection 28:278–281

    Google Scholar 

  26. Zaidi Y, Hastings M, Murray J, Hassan R, Kurshid M, Mahendra P (2001) Quinolone resistance in neutropenic patients: the effect of prescribing policy in the UK and Pakistan. Clin Lab Haematol 23:39–42

    Google Scholar 

  27. Delarive P, Baumgartner JD, Glauser MP, Cometta A (2000) Evaluation de la prophylaxie antibiotique chez les patients neutropéniques avec hémopathie maligne. Schweiz Med Wochenschr 130:1837–1844

    Google Scholar 

  28. Donnelly JP, Maschmeyer G, Daenen S, for the EORTC Gnotobiotic Project Group (1992) Selective oral antimicrobial prophylaxis for the prevention of infection in acute leukemia—ciprofloxacin versus co-trimoxazole plus colistin. Eur J Cancer 28A:873–878

    Google Scholar 

  29. Gomez L, Garau J, Estrada C, Marquez M, Dalmau D, Xercavins M, Marti JM, Estany C (2003) Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli. Cancer 97:419–424

    Google Scholar 

  30. Mannan P, Kibbler CC, Noone P (1988). Activity of ciprofloxacin and colistin against Pseudomonas aeruginosa isolates from neutropenic patients: a possible approach to prophylaxis. J Antimicrob Chemother 22:953–954

    Google Scholar 

  31. Martino R, Subira M, Altes A, Lopez R, Sureda A, Domingo-Albos A, Pericas R, Brunet S (1998) Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity. Acta Haematol 99:206–211

    Google Scholar 

  32. de Bock R, Cometta A, Kern WV, Aoun M, Caballero D, Engelhard D, Schaffner A, Galazzo M, Paesmans M, Vandenbergh M, Viscoli C (2001) Incidence of single agent gram-negative bacteremia in neutropenic cancer patients in EORTC-IATG trials of empirical therapy for febrile neutropenia. Program and abstracts of the 41st Interscience Conference of Antimicrobial Agents and Chemotherapy. Abstract no. L773

  33. Krüger WH, Hornung RJ, Hertenstein B, Kern WV, Kröger N, Ljungman P, Zander AR, and the EBMT (2001) Practices of infectious disease prevention and management during hematopoietic stem cell transplantation: a survey from the European group for blood and marrow transplantation. J Hematother Stem Cell Res 10:895–903

    Google Scholar 

  34. Gracia Escudero A, Gonzalez MM, Gimenez Garrido F, Clavero Farre C, Garcia Perez MJ, Alvarez Corral G, Reyes Bertos A, Villegas Maldonado G, Rodriguez Cuartero A (2003) Estudio prospectivo y controlado, no aleatorizado de tres cohortes sobre la efectividad de dos pautas antibioticas, levofloxacino y contrimoxazol, en profilaxis antibacteriana de pacientes neutropenicos. Med Clin (Barcelona) 120:321–325

    Google Scholar 

  35. Kern WV, Hay B, Kern P, Marre R, Arnold R (1994) A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis. Antimicrob Agents Chemother 38:465–472

    Google Scholar 

  36. National Committee for Clinical Laboratory Standards (1997) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd edn. Approved standard M100-S7. NCLLS, Wayne, PA

  37. Blackwood RA, Rode CK, Pierson CL, Bloch CA (1997) Pulsed-field gel electrophoresis genomic fingerprinting of hospital Escherichia coli bacteraemia isolates. J Med Microbiol 46:506–510

    Google Scholar 

  38. Oethinger M, Conrad S, Kaifel K, Cometta A, Bille J, Klotz G, Glauser MP, Marre R, the EORTC International Antimicrobial Therapy Cooperative Group, Kern WV (1996) Molecular epidemiology of fluoroquinolone-resistant Escherichia coli bloodstream isolates from patients admitted to European cancer centers. Antimicrob Agents Chemother 40:387–392

    Google Scholar 

  39. Oethinger M, Jellen-Ritter AS, Conrad S, Marre R, Kern WV (1998) Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis. Infection 26:379–384

    Google Scholar 

  40. Tascini C, Menichetti F, Bozza S, Fedele M, Preziosi R, Allegrucci M, del Favero A, Micozzi A, Martino P, Bistoni F (1999) Molecular typing of fluoroquinolone-resistant and fluoroquinolone-susceptible Escherichia coli isolated from blood of neutropenic cancer patients in a single center. Clin Microbiol Infect 5:457–461

    Google Scholar 

  41. Mandal P, Kapil A, Goswami K, Das B, Dwivedi SN (2001) Uropathogenic Escherichia coli causing urinary tract infections. Indian J Med Res 114:207–211

    Google Scholar 

  42. Threlfall EJ, Cheasty T, Graham A, Rowe B (1997) High-level resistance to ciprofloxacin in Escherichia coli. Lancet 349:403

    Google Scholar 

  43. Contrepois M, Bertin Y, Pohl P, Picard B, Girardeau JP (1998) A study of relationships among F17a producing enterotoxigenic and non-enterotoxigenic Escherichia coli strains isolated from diarrheic calves. Vet Microbiol 64:75–81

    Google Scholar 

  44. Dekker AW, Rozenberg-Arska M, Verhoef J (1987) Infection prophylaxis in acute leukaemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med 106:7–12

    Google Scholar 

  45. Yeh SP, Hsueh EJ, Yu MS, Wu H, Wang YC (1999) Oral ciprofloxacin as antibacterial prophylaxis after allo-BMT: a reappraisal. Bone Marrow Transplant 24:1207–1211

    Google Scholar 

  46. Munoz L, Martino R, Subira M, Brunet S, Sureda A, Sierra J (1999) Intensified prophylaxis of febrile neutropenia with ofloxacin plus rifampin during severe short-duration neutropenia in patients with lymphoma. Leuk Lymphoma 34:585–589

    Google Scholar 

  47. Gomez-Martin C, Sola C, Hornedo J, Perea S, Lumbreras C, Valenti V, Arcediano A, Rodriguez M, Salazar R, Cortes-Funes H, Hidalgo M (2000) Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cancer patients: results of a randomized clinical trial. J Clin Oncol 18:2126–2134

    Google Scholar 

  48. Palau J, Picon I, Angel Climent M, Marti R, Aznar E, Sanjuan MC, Maiquez J (2001) [Infection in patients with neutropenia that undergo an autologous peripheral blood stem cell transplant due to breast cancer]. Enferm Infecc Microbiol Clin 19:422–427

    Google Scholar 

  49. Salazar R, Sola C, Maroto P, Tabernero JM, Brunet J, Verger G, Valenti V, Cancelas JA, Ojeda B, Mendoza L, Rodriguez M, Montesinos J, Lopez-Lopez JJ (1999) Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 23:27–33

    Google Scholar 

  50. Bow EJ, Loewen R, Vaughan D (1995) Reduced requirement for antibiotic therapy targeting gram-negative organisms in febrile, neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones. Clin Infect Dis 20:907–912

    Google Scholar 

  51. Gilbert C, Meisenberg B, Vredenburgh J, Ross M, Hussein A, Perfect J, Peters WP (1994) Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol 12:1005–1011

    Google Scholar 

  52. Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Kalish LA, Finberg R (1991) Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation 51:630–636

    Google Scholar 

  53. Lopez A, Soler JA, Julia A, Novo A, Bueno J (1994) [Prophylaxis with ciprofloxacin in postchemotherapy neutropenia in acute myeloid leukemia] Med Clin (Barcelona) 102:81–85

    Google Scholar 

  54. Nagatomo A, Watanabe K, Kunikane H, Okamoto H, Kunitoh H (1998) A randomized controlled trial of sulfamethoxazole/trimethoprim plus norfloxacin versus sulfamethoxazole/trimethoprim alone for the prophylaxis of bacterial infection during chemotherapy for lung cancer. Lung Cancer 19:121–125

    Google Scholar 

  55. Prentice HG, Hann IM, Nazareth B, Paterson P, Bhamra A, Kibbler CC (2001) Oral ciprofloxacin plus colistin: prophylaxis against bacterial infection in neutropenic patients. A strategy for the prevention of emergence of antimicrobial resistance. Br J Haematol 115:46–52

    Google Scholar 

  56. Schroeder M, Schadeck-Gressel A, Selbach J, Westerhausen M (1992) Antibiotic prophylaxis with gyrase inhibitors during cytostatically induced granulocytopenia in patients with solid tumors: a double-blind prospective randomized study. Onkologie 15:476–479

    Google Scholar 

  57. Tjan-Heijnen VC, Postmus PE, Ardizzoni A, Manegold CH, Burghouts J, van Meerbeeck J, Gans S, Mollers M, Buchholz E, Biesma B, Legrand C, Debruyne C, Giaccone G, for the EORTC Lung Cancer Group (2001) Reduction of chemotherapy-induced febrile leukopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol 12:1359–1368

    Article  CAS  PubMed  Google Scholar 

  58. Yamada T, Dan K, Nomura T (1993) Prevention of bacterial and fungal infections in acute leukemia patients: a new and potent combination of oral norfloxacin and amphotericin B. Intern Med 32:710–715

    Google Scholar 

  59. Yoo JH, Huh DH, Choi JH, Shin WS, Kang MW, Kim CC, Kim DJ (1997) Molecular epidemiological analysis of quinolone-resistant Escherichia coli causing bacteremia in neutropenic patients with leukemia in Korea. Clin Infect Dis 25:1385–1391

    CAS  PubMed  Google Scholar 

  60. Bochud PY, Calandra T, Francioli P (1994) Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med 97:256–264

    Article  CAS  PubMed  Google Scholar 

  61. Bow EJ, Mandell LA, Louie TJ, Feld R, Palmer M, Zee B, Pater J (1996) Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Ann Intern Med 125:183–190

    Google Scholar 

  62. Timmers GJ, Dijstelbloem Y, Simoons-Smit AM, van Winkelhoff AJ, Touw DJ, Vandenbroucke-Grauls CM, Huijgens PC (2004) Pharmacokinetics and effects on bowel and throat microflora of oral levofloxacin as antibacterial prophylaxis in neutropenic patients with haematological malignancies. Bone Marrow Transplant 33:847–853

    Google Scholar 

  63. Razonable RR, Litzow MR, Khaliq Y, Piper KE, Rouse MS, Patel R (2002) Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis 34:1469–1474

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Infectious Diseases and Travel Medicine, Department of Medicine, University Hospital, Hugstetter Strasse 55, 79106, Freiburg, Germany

    W. V. Kern & J. Bohnert

  2. Section of Infectious Diseases and Clinical Immunology, Ulm University Hospital and Medical Center, 89070, Ulm, Germany

    K. Klose, A. S. Jellen-Ritter, P. Kern & S. Reuter

  3. Department for Pathology and Laboratory Medicine, Yale University School of Medicine, Yale New Haven Hospital, Connecticut, CT, 06510-3202, USA

    M. Oethinger

  4. Department of Medical Microbiology and Hygiene, Ulm University Hospital and Medical Center, 89070, Ulm, Germany

    H. von Baum & R. Marre

Authors
  1. W. V. Kern
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Klose
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. S. Jellen-Ritter
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Oethinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Bohnert
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Kern
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Reuter
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. von Baum
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R. Marre
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. V. Kern.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kern, W.V., Klose, K., Jellen-Ritter, A.S. et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 24, 111–118 (2005). https://doi.org/10.1007/s10096-005-1278-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-005-1278-x

Keywords

Search

Navigation